Tenofovir compared with adefovir, how much to improve the efficacy?

- Nov 17, 2017 -

Tenofovir compared with adefovir, how much to improve the efficacy?

 

Tenofovir and adefovir are the same, belong to nucleoside drugs in the nucleotides, both similar in nature, both of the antiviral activity is very poor. One reason for this is that adefovir now uses only one third of the optimal dose for nephrotoxicity, 300 mg of tenofovir a day, 10 mg of adefovir daily, and a difference in plasma concentrations of 2.29: 0.22 μg / h / ml in vitro The difference between the two experiments 1000 times.

 

International clinical trials done in 2008 compared with adefovir-controlled 12-month treatment: Viral negative (<400 cp / ml) Tenofovir has 93% of patients in the "Little Sanyang" and adefovir has only 63%; Tenofovir is much better than adefovir in "big three positive" patients.

 

However, as a generalization of nucleoside drugs, the conversion of serum E antigen to E antibody is very low. Tenofovir was only 20% more in one year and only 12% of adefovir. HBsAg negative little. In a multi-drug clinical trial reported in the United Kingdom in 2010, the probability of getting negative for HBV DNA was significantly higher for tenofovir, a nucleoside that was considered more antiviral.